The role of metronidazole in COVID-19

Phase 2

• Conditions: COVID-19.; U07.1; COVID-19

• Registration Number: IRCT20200608047686N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inpatients with Pneuomonia Due to COVID-19

Exclusion Criteria

Hypersensitivity Reactions to Metronidazole
Pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
O2 Saturation. Timepoint: within 7 days from initiation of study treatmentat. Method of measurement: Pulse Oximetry.

Secondary Outcome Measures

Name	Time	Method
Mortality. Timepoint: daily up to death during hospitalizatiion. Method of measurement: Patient death.;Lenght of hospitat stay. Timepoint: daily up to discharge. Method of measurement: Inpatient days.